Delcath Systems to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Delcath Systems, Inc. (DCTH) will attend investor conferences to discuss its focus on treating liver cancers. Management will be at Leerink Partners Global Biopharma Conference on March 13, 2024, in Miami Beach, FL, and the 36th Annual ROTH Conference on March 18 - 19, 2024, in Dana Point, CA.

NEW YORK, March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Company management will be attending the following upcoming investor conferences:

Leerink Partners Global Biopharma Conference 
Date: March 13, 2024
Location: Miami Beach, FL

36^th Annual ROTH Conference
Date: March 18 - 19, 2024
Location: Dana Point, CA

Management is scheduled to host one-on-one meetings throughout the event. Investors interested in arranging one-on-one meetings should contact your conference representative. You may also call or email Ben Shamsian of Lytham Partners at 646-829-9701, or shamsian@lythampartners.com.

About Delcath Systems, Inc., CHEMOSAT and HEPZATO KIT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

Contact:

Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-upcoming-investor-conferences-302084134.html

SOURCE Delcath Systems, Inc.

FAQ

When will Delcath Systems, Inc. attend the Leerink Partners Global Biopharma Conference?

Delcath Systems, Inc. (DCTH) will attend the Leerink Partners Global Biopharma Conference on March 13, 2024, in Miami Beach, FL.

Where is the 36th Annual ROTH Conference taking place?

The 36th Annual ROTH Conference will be held on March 18 - 19, 2024, in Dana Point, CA.

How can investors arrange one-on-one meetings with Delcath Systems, Inc. management?

Investors interested in arranging one-on-one meetings with Delcath Systems, Inc. management should contact their conference representative or Ben Shamsian of Lytham Partners at 646-829-9701, or shamsian@lythampartners.com.